



HAL
open science

Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT.

Anne Ségolène Cottureau, Michel Meignan, Christophe Nioche, Nicolò Capobianco, Jérôme Clerc, Loïc Chartier, Laetitia Vercellino, Olivier Casasnovas, Catherine Thieblemont, Irène Buvat

► To cite this version:

Anne Ségolène Cottureau, Michel Meignan, Christophe Nioche, Nicolò Capobianco, Jérôme Clerc, et al.. Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT.. *Annals of Oncology*, 2020, 10.1016/j.annonc.2020.11.019 . hal-03089539v1

HAL Id: hal-03089539

<https://hal.science/hal-03089539v1>

Submitted on 28 Dec 2020 (v1), last revised 14 Jan 2022 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title page

Title. Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT.

Anne-Ségolène Cottureau^{1,2}, Michel Meignan³, Christophe Nioche², Nicolò Capobianco^{4,5}, Jérôme Clerc¹, Loic Chartier⁶, Laetitia Vercellino⁷, Olivier Casasnovas⁸, Catherine Thieblemont⁹, Irène Buvat²

1. Department of Nuclear Medicine, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.

2. LITO laboratory, UMR 1288 Inserm, Institut Curie, Université Paris Saclay, Orsay, France.

3. Lysa Imaging, Henri Mondor University Hospital, AP-HP, University Paris East, Créteil, France.

4. Siemens Healthcare GmbH, Erlangen, Germany.

5. Technical University of Munich, Munich, Germany.

6. The Lymphoma Academic Research Organisation , Statistic, Centre Hospitalier Lyon Sud, Pierre-Benite, France.

7. Department of Nuclear Medicine, Saint-Louis Hospital, AP-HP, Paris, France.

8: Department of Hematology, University Hospital of Dijon, Dijon, France.

9: Department of Hematology, Saint Louis Hospital, APHP, Paris, France.

First Author and corresponding author

Dr Anne-Ségolène Cottureau

Nuclear Medicine Department, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France.

Mail: annesegolene.cottereau@aphp.fr

Tel: +33 1 58 41 41 41

ORCID iD : 0000-0002-4805-4564

Running head:

Baseline lesion dissemination and metabolic volume measured by PET in DLBCL

Key words:

lesion dissemination- metabolic tumor volume- PET/CT - DLBCL

Highlights

1. Large lesion dissemination measured by high SDmax was a strong prognosticator of shorter PFS and OS in DLBCL patients
2. SDmax results in an accurate risk stratification at baseline, even in advanced Ann Arbor stage patients.
3. SDmax and MTV are independent prognosticators and identified a high risk group among DLBCL patients responding to R-CHOP.
4. SDmax combined with MTV seems superior to IPI or NCCN-IPI stratifications and promising to guide the therapeutic strategy.

Abstract: 274 words (maximum 300 words)

Manuscript body: 3034 words + 900 words (figures+tables) (< 4500 words, main body + tables/figures)

Tables/Figures: 3 tables/ 3 figures =900 words

Supplementary Tables/Figures: 0

References: 27

Potential Conflicts-of-Interest Disclosures

Anne-Ségolène Cottereau: none

Michel Meignan: none

Christophe Nioche : none

Nicolò Capobianco: employee at Siemens Healthcare GmbH

Jérôme Clerc: none

Loic Chartier: none

Laetitia Vercellino: none

Olivier Casasnovas: research funding from Roche, Takeda, Gilead, advisory board and honoraria from Celgene, Roche, Takeda, Gilead, BMS, Merck, Abbvie, Janssen outside the submitted work

Catherine Thieblemont: Honoraria from Roche, Amgen, Janssen, Celgene, Gilead Science/Kyte; consulting/advisory role from Roche, Gilead Sciences, Janssen, Celgene, Novartis; research funding and travel, accommodations, expenses from Roche, Novartis

Irène Buvat: none

This study has been approved by an ethic committee: Comité de Protection des Personnes Sud-Est III, Hôpital HOTEL-DIEU, Place de l'Hôpital (Etude REMARC
Réf : 2009 - 006B; Eudract N° : 2008-008202-52)

Title

Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT.

Abstract

Background: We analysed the prognostic value of a new baseline PET parameter reflecting the spread of the disease: the largest distance between two lesions (Dmax). We tested its complementarity to metabolic tumor volume (MTV) in a large cohort of DLBCL patients from the REMARC trial (NCT01122472).

Patients and methods: MTVs were defined using the 41% SUVmax threshold. From the three dimensional coordinates, the centroid of each lesion was automatically obtained and considered as the lesion location. The distances between all pairs of were calculated. Dmax was obtained for each patient and normalized with the body surface area (SDmax).

Results: 291 patients were included, 91% had an advanced stage and 71% IPI \geq 3. High vs low SDmax significantly impacted PFS ($P<0.0001$) and OS ($P=0.0027$). Patients with SDmax >0.32 m⁻¹ (n=82) had a 4y-PFS and OS of 46% and 71% respectively against 77% and 87% respectively for patients with low SDmax. High SDmax and high MTV were independent prognostic factors of PFS ($P=0.0001$ and $P=0.0010$ respectively) and OS ($P=0.0028$ and $P=0.0004$ respectively). Combining MTV and SDmax yielded three risk groups with no (n=109), one (n=122) or two (n=59) factors ($P<0.0001$ for both PFS and OS). The 4-year PFS were 90%, 63%, 41% respectively, the 4-year OS 95%, 79%, 66% respectively. In addition, patients with at least 2 of the 3 factors including high SDmax, high MTV, ECOG \geq 2 had a higher number of CNS relapse ($P=0.017$).

Conclusions: SDmax is a simple feature that captures lymphoma dissemination, independent from MTV. These two PET metrics, SDmax and MTV, are complementary to characterise the disease, reflecting the tumor burden and its spread. This score appeared promising for DLBCL baseline risk stratification.

Introduction

Diffuse large B cell lymphoma (DLBCL) is the largest subtype of malignant lymphoma all over the world. It is a very heterogeneous disease entity, with multiple histologic subtypes, morphologic variants (eg primary mediastinal B-cell lymphoma), specific virus (EBV, HV8), specific genetic abnormalities (such as MYC and BCL2, and/or BCL6 rearrangements), and derived from different cells of origin (either germinal center B-cell-like (GCB) or activated B-cell-like (ABC)) (1). Further molecular categorizations based on recurrent somatic mutations have been recently proposed (2,3). Despite the complex heterogeneity of DLBCLs, the R-CHOP regimen (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is regarded as a standard for first line DLBCL therapy, offering a complete remission rate of around 80% (4). Nonetheless, the prognosis of the patients who experience disease recurrence or refractory disease is poor. In clinical practice, a number of features are of value to predict overall survival and disease free survival, including age, LDH, performance status, disease stage, number of involved extranodal sites and are incorporated in prognostic models such as the International Prognostic Index (IPI) and more recently the National Comprehensive Cancer Network (NCCN)-IPI (5)(6). Unfortunately, all failed identifying the high-risk patients.

In the past few years, an imaging biomarker calculated from FDG PET has been proven useful to improve the risk classification of patients: the total metabolic tumor volume (MTV). This

biomarker estimates the total tumor burden more accurately than the simple dimension of the bulk or even the Ann Arbor Stage. High baseline MTV results in significantly shorter progression-free survival (PFS) and overall survival (OS) in many lymphoma subtypes (7-11). In DLBCL, the prognostic value of MTV overcoming usual prognostic indices(12) is now well established, with data from large prospective series (10,13,14). Even in patients responding to first line R-CHOP therapy, MTV remains a best prognostic factor, as has been recently published from the REMARC study(15) involving patients aged from 60 to 80 years (16). In this cohort, a high MTV identified a subset of approximately half of the patients with a 20-point reduction in 4-year progression free survival (PFS) and overall survival (OS).

However, the heterogeneity of the distribution of the lesions is not considered with MTV measurement. Indeed DLBCL often involves multiple disseminated nodal sites possibly associated with extra nodal sites, sometimes with mutational heterogeneity impacting outcome (17). Recently, a simple imaging feature measured from FDG PET scans and reflecting lesions dissemination has been introduced in DLBCL patients: the distance between the two lesions that were the furthest apart (Dmax) (18). A high Dmax was associated with an adverse outcome, independently of MTV, in a cohort of 95 patients with an advanced stage DLBCL. A straightforward model combining MTV and Dmax was demonstrated to be effective at stratifying patients with higher accuracy than Ann Arbor classification. In that context, the objectives of the present study were to confirm the prognostic value of this new PET feature reflecting tumor dissemination, in a different and larger cohort of DLBCL patients, and to test whether combining it with MTV could improve risk stratification at baseline.

Methods

From the REMARC trial (NCT01122472), 301 patients with a baseline PET/CT (before any treatment) were available for retrospective review. All were part of a previous study already

published regarding MTV (16). The REMARC study design details have been reported elsewhere (15). Briefly, patients, 60-80 years old, ECOG PS 0-2, Ann Arbor stage II-IV at diagnosis, aaIPI ≥ 1 at diagnosis, with histologically-proven CD20+ DLBCL according to 2008 WHO criteria, and a complete response or partial response as defined by Cheson 2007 criteria (19) after 6 or 8 cycles of standard R-CHOP were included and randomized 1:1 to lenalidomide maintenance 25 mg/day or placebo for 21 of every 28-day cycle for 2 years. Baseline PET was not mandatory in the trial.

PET/CT analysis

Using the Beth Israel PET/CT viewer plugin for FIJI (20), MTVs were defined by two nuclear medicine physicians (ASC, LV) using 41% SUVmax threshold, blinded to patient outcome. Regional volumes automatically identified by the software were checked visually to confirm inclusion of only pathological lesions and labelled to distinguish between the different nodal sites, using 10 labels (cervical left/right; axillary L/R; mediastinal; abdominal; iliac L/R; inguinal L/R) and extranodal sites. Bone marrow involvement was included in the volume measurement only if there was focal uptake as previously described (21). From the three dimensional coordinates of the metabolic volume of each lymphoma lesion, the center of mass (centroid) of each lesion was automatically obtained and was considered as the lesion location. The distances between all pairs of lesions (including both nodal and extra nodal lesions) were calculated by using the Euclidian formula $AB = \sqrt{(xb - xa)^2 + (yb - ya)^2 + (zb - za)^2}$ (18) with LIFEx software (22). The largest distance Dmax was deduced in each patient and normalized by the patient body surface area (BSA), given by $\sqrt{(\text{weight} \times \text{height})/3600}$ yielding the standardized Dmax called SDmax thereafter.

Statistical analysis

For the current study, only patients with BSA data available and with at least 2 detectable lesions allowing distance measurement were included. The optimal MTV and SDmax cut-off values for PFS and OS were determined using Receiver Operating Curve analysis and X-tile analysis and confirmed by a training validation method. A random sample of two-thirds of the patients was the training cohort; the remaining one-third was the validation cohort. The cut-off values were chosen as the values maximizing the Youden index defined as the sum of sensitivity and specificity minus one. PFS was measured from the date of randomization to the date of death from any cause, disease relapse or progression, or the date of last contact. CNS relapse was analysed as a specific event and prediction of CNS relapse was separately analysed. OS was calculated from the date of randomization until the date of death from any cause or the date of last contact. Survival functions were calculated using Kaplan-Meier estimates, and comparisons between categories were made with the log-rank test. Characteristics of populations were compared using Fischer's exact test for discrete variables and Mann Whitney test for continuous variables. Variables considered for model design included MTV, Dmax, SDmax, extranodal sites, ECOG PS, LDH, Ann Arbor stage, IPI. Univariate and multivariate analyses were performed using Cox proportional hazard models. Spearman correlation coefficient rho was calculated between SDmax and the number of nodal involved sites. Test results were interpreted as significant if the 2-sided P-value was less than 0.05. Statistical analyses were conducted using MedCalc software (MedCalc Software, Ostend, Belgium) and X-tile 3.6.1 software (Yale University, New Haven, CT).

Results

Among the 301 patients, 11 patients were excluded (2 with BSA data not available, 9 without at least two distinct lesions). The 290 patients' baseline clinical characteristics are shown in

Table 1. After a median follow-up of 5 years, 88 patients (30%) had a PFS event and 54 patients (19%) had an OS event. The 4-y PFS was 69% and 4-y OS was 83%.

PET features

Median baseline MTV was 253 cm³ (IQR: 86 to 556). Using a cut-off value of 220 cm³ previously found to be optimal for that patient cohort (16), the sensitivity and specificity were 72% and 54% for PFS and 80% and 52% for OS. Half of the patients (n=158 patients, 55%) had a MTV greater than 220 cm³. Median Dmax was 42 cm (interquartile range [IQR]: 23 to 63), median SDmax was 0.23 m⁻¹ ([IQR]: 0.13 to 0.33).

ROC optimal cut-off value maximizing the Youden index for SDmax was 0.32 m⁻¹ with a sensitivity and specificity of 43% and 80% respectively for PFS. Using this cut-off, sensitivity and specificity were 43% and 77% respectively for OS. Areas under the ROC curves (AUC) were 0.64 ($P=0.0002$) for PFS and 0.62 ($P=0.005$) for OS. X-tile procedure yielded a cut-off value of 0.38 m⁻¹ for PFS ($P<0.0001$) and 0.37 m⁻¹ for OS ($P=0.0099$), with a sensitivity of 23% for PFS and 28% for OS, and a specificity of 92% and 88% respectively.

Patient characteristics stratified according to high or low SDmax values are given in Table 1. A high SDmax was associated with advanced Ann Arbor stage (100% vs 88%, $P<0.001$), a high MTV (72% vs 48%, $p<0.001$), more than one extra nodal sites involved (68% vs 44%, $p<0.001$), IPI score 3-5 (85% vs 65%, $p<0.001$) and high NCCN-IPI score (82% vs 64%, $P=0.006$). SDmax was correlated with the number of nodal involved sites ($\rho=0.732$, $P<0.0001$; Figure 1). There was no significant difference between molecular characteristics of patients (cell of origin determined with Hans algorithm and with Nanostring, and BCL2 or MYC protein overexpression) with high and low SDmax.

Univariate analysis (Table 2, Figure 2 AB)

The presence of more than one extranodal site was a significant adverse factor for both PFS and OS. The number of more than 4 nodal areas involved was prognostic only on PFS. Among the features characterizing lymphoma lesions, Dmax, SDmax and MTV were the most significant to predict both PFS and OS (table 2). A high SDmax ($>0.32 \text{ m}^{-1}$) was significantly associated with a shorter PFS ($P < 0.0001$, HR=2.7) and OS ($P = 0.0027$, HR=2.3) (table 2). The 4-year PFS and OS was 46% and 71% respectively for patients with high SDmax ($>0.32 \text{ m}^{-1}$) versus 77% and 87% for patients with a low SDmax (Figure 2 AB).

Although 59 patients (20%) had both a high SDmax ($> 0.32 \text{ m}^{-1}$) and a high MTV ($>220 \text{ cm}^3$) and 109 patients (38%) had both a low SDmax and a low MTV, 122 patients (42%) had discordant MTV and SDmax: 23 patients (8%) had a high SDmax with a low MTV, while 99 patients (34%) had a low SDmax with a high MTV.

In a sub-analysis of Ann Arbor advanced III-IV stage patients (n=264), SDmax remained a significant prognosticator for both PFS (HR=2.5; $P < 0.0001$) and OS (HR=2.1, $P=0.0059$). SDmax also remained a significant prognosticator for PFS in both Lenalidomide arm (HR=2.2, $p=0.012$) and placebo arm (HR=3.5, $p<0.0001$). In addition, patients with high SDmax had a higher risk of early relapse than patients with low SDmax, with 2-year PFS of 71% vs 87% in Lenalidomide arm and 2y-year PFS of 53% vs 84% in the placebo arm.

Multivariable analysis (Table 3)

Combining the 2 PET parameters (Model 1 in Table 3) showed that SDmax and MTV were independent prognostic factors of both PFS (HR=2.4, $P=0.0001$ and HR=2.2, $P=0.001$, respectively) and OS (HR=1.8, $P=0.028$ and HR=3.3, $P=0.0004$ respectively). Three risk categories could be distinguished based on SDmax and MTV (Figure 2 CD and Figure 3) : group 1 (n=109) with low SDmax ($\leq 0.32 \text{ m}^{-1}$) and low MTV ($\leq 220 \text{ cm}^3$); group 2 with either high SDmax or high MTV (n=121), and group 3 with both high SDmax and high MTV (n=59).

These three groups had significantly different 4-year PFS rates of 90% (group 1), 63% (group 2), and 41% (group 3), respectively (group 1 vs group 2: HR = 2.1 and $p = 0.0042$; group 1 vs group 3: HR = 4.9 and $P < 0.0001$; group 2 vs group 3: HR = 2.3 and $P = 0.0004$; Figure 2C). They also had significantly different 4-year OS rates of 95% (group 1), 79% (group 2), and 66% (group 3) respectively (group 1 vs group 2: HR=3.0 and $P=0.0024$; group 1 vs group 3: HR=6.5 and $P<0.0001$; group 2 vs group 3 : HR=1.8 and $P=0.044$; Figure 2 D). Finally, patients with a high MTV but a low SDmax ($n=99$) had similar PFS ($P=0.64$) and OS ($P=0.39$) to those of patients with a high SDmax and a small MTV ($n=26$) (Figure 3).

Model 2 in Table 3 included all individual factors which were significant in univariate analysis. SDmax, MTV and ECOG remained independent prognosticators for PFS ($P=0.0001$, $P=0.037$, $P=0.0010$ respectively). Interestingly, these 3 factors combined were associated with CNS relapse. Patients with 2 or 3 adverse factors among high SDmax, high MTV, ECOG 2-3 ($n=79$) had a higher risk of CNS relapse ($P=0.017$), namely 6% contrasting with 1% in the group without or with a single adverse factor ($n=211$). By contrast, MTV combined with ECOG alone failed to identify CNS relapse (data not shown).

In model 3 testing IPI with MTV and SDmax (Model 3, Table 3), only MTV and SDmax remained significant for PFS ($P=0.0001$ and $P=0.0016$ respectively). For OS, only MTV was significant ($P=0.0006$) whereas SDmax did not reach significance ($P = 0.061$).

Discussion

Early identification of DLBCL patients who are unlikely to be cured with R-CHOP is an important step to enable testing of alternative treatment approaches. This requires a refined risk-scoring approach where metrics extracted from baseline PET could play a significant role. Among them, the high prognostic value of MTV is now established. In the present study, we

showed in a large series of 290 elderly DLBCL patients in response to first line therapy that a new feature SDmax, which is the largest distance between lymphoma sites normalized with the body surface area, had a prognostic impact on DLBCL outcome. This parameter, capturing the spread of the disease, was independent from MTV for outcome prediction. These two biomarkers combined identified an ultra-risk group of DLBCL patients before treatment. These results confirmed our previous data in a series of 95 DLBCL young patients undergoing an interim PET guided therapy (18).

Textural and morphological characterization of tumoral metabolic patterns in 18FDG-PET have been investigated in lymphoma patients, with little evidence so far that they provide additional diagnostic or prognostic information (23-26), except for MTV. Regarding heterogeneity, Ceriani and colleagues showed in Primary Mediastinal B-cell Lymphoma that the metabolic heterogeneity (MH) (25,26) of the mass was a predictor of outcome. However when this parameter was applied to a population of 141 DLBCL patients from the prospective SAKK38/07 study (NCT00544219) (26), in multivariate analysis only MTV retained statistical significance for predicting outcome. In all these studies, textural parameters were computed from one (the largest or with the highest SUV) up to 3 tumor sites which might not adequately reflect the disease heterogeneity. In addition, lymphoma often involves lymph nodes and extranodal sites. The texture analysis of only one to three lesions might thus not be sufficient to characterize lymphoma disease. The need to account for the disease heterogeneity is suggested in a recent report (17) that highlights the spatial heterogeneity based on whole exome sequencing in two tumors from the same DLBCL patient at baseline. Consistent with the importance of taking the spatial heterogeneity of the disease into account, the prognostic value of the largest diameter of a single bulk mass is much lower than that of the MTV, which includes all or most lymphoma lesions (9-11).

Our results are in line with the effort to characterize the heterogeneity of the disease. Here, we have normalized Dmax with the body surface area to take into account the size and height of each patient, yielding the Standardized Dmax (SDmax), with still a strong prognostic value for outcome. SDmax, which intuitively reflects the dissemination of the disease, outperformed Ann Arbor stage for prognostication, and therefore remained relevant even among patients with an advanced disease. It is highly correlated with the number of nodal sites involved, but much

more significant for PFS or OS prediction, suggesting the prognostic importance of lymphoma spread. (27). Even if Lenalidomide globally improves patients PFS in the REMARC trial, its effect seems more pronounced in the high SDmax group than in the low SDmax group: patients with high SDmax have a 4-year PFS of 66.6 % in Lenalidomide arm contrasting with a 4-year PFS of 20.8% in the placebo group. For patients with low SDmax, the difference was much lower, with a 4-year PFS of 81.6% in Lenalidomide arm vs 73.1% in the placebo group. In addition, patients with high SDmax had a higher risk of early relapse than patients with low SDmax, with 2-year PFS of 71% vs 87% in Lenalidomid arm and 2-year PFS of 53% vs 84% in the placebo arm.

SDmax is a very simple feature that captures the disease dissemination. It is a 3D feature that is easy to understand and calculate. Unlike sophisticated radiomic features often difficult to interpret from a biological point of view, SDmax intuitively reflects the spatial migration of the disease to different sites. Being a distance between the centroids of two lesions, it is not expected to be highly impacted by the PET/CT scanner performance and generation, facilitating its widespread use. In addition, it is not substantially impacted by MTV measurements, since the centroid of the VOI does not change much with the size of the VOI.

In the present study, SDmax and MTV had independent predictive value. We suggested a prognostic scoring system based on these two features extracted from the baseline PET/CT scan that are complementary in that sense that they characterise two different aspects of the disease: the tumor burden and its dissemination. This score appeared more beneficial for patient risk stratification in guiding therapy than the current Ann Arbor staging system, which failed to predict outcome in this cohort, or than the current prognostic indices such as IPI. This model combining two PET features significantly separated three different prognostic groups: group 1 with no risk factor, group 2 with one risk factor, group 3 with two. Specifically, this score could identify a group of patients with a poor prognosis, even in response after R-CHOP, for whom clinicians might consider alternative treatment approaches. Indeed, patients with high baseline MTV ($>220 \text{ cm}^3$) and high SDmax ($>0.32 \text{ m}^{-1}$) had a much worse prognosis than the other patients with 4-year PFS of 41% and 4-year OS of 66%.

This score based on the SDmax and MTV PET imaging features will have to be correlated with other individual clinical or biological data in larger cohorts. Indeed, using the same REMARC cohort, it has been published recently that among all investigated clinical and biological factors, only ECOG complemented MTV, yielding a new simple score to discriminate high risk patients (16). It has been suggested that the combination of this score with other molecular profiles recently described in DLBCL could help select new therapeutic strategies(3). Investigating the combination of this score with SDmax is challenging in the present cohort because the overall favourable outcome of patients (responders to R-CHOP) resulted in a relatively low number of events, reducing the statistical power of an analysis involving small subgroups of patients characterized by different factors. Despite this limitation, SDmax, MTV and ECOG remained independent significant predictors for PFS. For OS, SDmax did not reach significance possibly due to statistical power limitation. In addition, a higher rate of CNS relapse was observed in the group with 2 or 3 adverse factors (high MTV, high SDmax, ECOG 2-3) whereas MTV and ECOG failed to predict CNS relapse, although these data should be interpreted with caution due to the small number of CNS relapse. Large studies are needed to determine what is the best combination of prognostic factors and what are the easiest factors to use in clinical routine. Standardization of MTV calculation is ongoing and will be soon achieved at an international level (28). Although SDmax is in its early stage, our results strongly suggest that current prognostic index could be refined including such a disease dissemination feature derived from PET imaging. Current tumor burden surrogates and Ann Arbor classification might be reconsidered given that baseline quantitative PET metrics are of value for optimizing personalized management.

Conclusion

By reflecting information regarding the dissemination of the disease, SDmax complements the lymphoma tumor burden measured by MTV. A simple score based on MTV and SDmax therefore enhances the prognostic value of PET staging and appears promising to guide the therapeutic strategy. It should be of interest to understand which categories of patients have a high SDmax, and to correlate the group with both high MTV and large spread with the different groups identified using molecular data (2,3). These results warrant further assessment in other large cohorts and comparison with existing prognostic models to overcome the limitations of current clinical prognostic indices in DLBCL patients.

Acknowledgment of Research Support/Disclaimer: The REMARC clinical study and analyses were sponsored by the Lymphoma Academic Research Organisation (LYSARC) of France.

Authorship Contributions

Administrative support: LYSA-RC

Conception and design: ASC, IB, MM

Provision of study material or patients: CT, OC.

Collection and assembly of data: ASC, NC, LV.

Data analysis and interpretation: ASC, IB, CT, MM, LC, LV, CN.

Manuscript writing: ASC, IB, CT, MM, OC, JC.

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

References

1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, *et al.* The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* **2016**;127(20):2375-90 doi 10.1182/blood-2016-01-643569.
2. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, *et al.* Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *The New England journal of medicine* **2018**;378(15):1396-407 doi 10.1056/NEJMoa1801445.
3. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, *et al.* Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nat Med* **2018**;24(5):679-90 doi 10.1038/s41591-018-0016-8.
4. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, *et al.* Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood* **2010**;116(12):2040-5 doi 10.1182/blood-2010-03-276246.
5. International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. *The New England journal of medicine* **1993**;329(14):987-94 doi 10.1056/NEJM199309303291402.
6. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, *et al.* The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood* **2007**;109(5):1857-61 doi 10.1182/blood-2006-08-038257.
7. Cottreau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, *et al.* Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* **2016** doi 10.1093/annonc/mdw011.
8. Meignan M, Cottreau AS, Versari A, Chartier L, Dupuis J, Boussetta S, *et al.* Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **2016**;34(30):3618-26 doi 10.1200/JCO.2016.66.9440.
9. Cottreau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, *et al.* Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. *Blood* **2018**;131(13):1456-63 doi 10.1182/blood-2017-07-795476.
10. Mikhaeel NG, Smith D, Dunn JT, Phillips M, Moller H, Fields PA, *et al.* Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. *European journal of nuclear medicine and molecular imaging* **2016** doi 10.1007/s00259-016-3315-7.
11. Cottreau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, *et al.* Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with Diffuse Large B Cell Lymphoma. *Clinical cancer research : an official journal of the American Association for Cancer Research* **2016** doi 10.1158/1078-0432.CCR-15-2825.

12. Cottreau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, *et al.* Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL-Response. *Clinical cancer research : an official journal of the American Association for Cancer Research* **2016**;22(13):3414-5 doi 10.1158/1078-0432.CCR-16-0783.
13. Lale Kostakoglu MM, Laurie H. Sehn, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Günter Fingerle-Rowson, Andrea Knapp, Federico Mattiello, Tina Nielsen, Gila Sellam, Denis Sahin, Umberto Vitolo and Marek TrnĚn. Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. *Blood* **2017**;130:824; .
14. Schmitz C, Huttmann A, Muller SP, Hanoun M, Boellaard R, Brinkmann M, *et al.* Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. *Eur J Cancer* **2020**;124:25-36 doi 10.1016/j.ejca.2019.09.027.
15. Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, *et al.* Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **2017**;35(22):2473-81 doi 10.1200/JCO.2017.72.6984.
16. Vercellino L, Cottreau AS, Casasnovas RO, Tilly H, Feugier P, Chartier L, *et al.* High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP. *Blood* **2020** doi 10.1182/blood.2019003526.
17. Araf S, Korfi K, Bewicke-Copley F, Wang J, Cogliatti S, Kumar E, *et al.* Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. *Haematologica* **2020** doi 10.3324/haematol.2019.242206.
18. Cottreau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, *et al.* (18)F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine* **2020**;61(1):40-5 doi 10.2967/jnumed.119.229450.
19. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, *et al.* Revised response criteria for malignant lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **2007**;25(5):579-86 doi 10.1200/JCO.2006.09.2403.
20. Grossiord E TH, Passat N, *et al.* Hierarchies and shape –space for PET image segmentation 2015 IEEE 12th International Symposium on Biomedical Imaging (ISBI) **2015**;1118-1121.
21. Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, *et al.* Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. *European journal of nuclear medicine and molecular imaging* **2014**;41(6):1113-22 doi 10.1007/s00259-014-2705-y.
22. Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C, *et al.* LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. *Cancer Res* **2018**;78(16):4786-9 doi 10.1158/0008-5472.CAN-18-0125.
23. Parvez A, Tau N, Hussey D, Maganti M, Metser U. (18)F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival. *Ann Nucl Med* **2018**;32(6):410-6 doi 10.1007/s12149-018-1260-1.
24. Ben Bouallegue F, Tabaa YA, Kafrouni M, Cartron G, Vauchot F, Mariano-Goulart D. Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas. *Med Phys* **2017**;44(9):4608-19 doi 10.1002/mp.12349.

25. Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL, *et al.* Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. *Blood* **2018**;132(2):179-86 doi 10.1182/blood-2018-01-826958.
26. Ceriani L, Gritti G, Cascione L, Piroso MC, Polino A, Ruberto T, *et al.* SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. *Blood Adv* **2020**;4(6):1082-92 doi 10.1182/bloodadvances.2019001201.
27. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, *et al.* An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. *Blood* **2014**;123(6):837-42 doi 10.1182/blood-2013-09-524108.
28. Barrington SF, Meignan M. Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden. *Journal of nuclear medicine* : official publication, Society of Nuclear Medicine **2019**;60(8):1096-102 doi 10.2967/jnumed.119.227249.

Tables

Table 1 Patients characteristics

| Characteristics | Total Population n=290 | SDmax ≤0.32 m ⁻¹ n=208 | SDmax >0.32 m ⁻¹ n=82 | P value |
|-------------------------------|---------------------------|--------------------------------------|-------------------------------------|-------------|
| Female | 120 (41%) | 91 (44%) | 29 (35%) | 0.23 |
| Ann Arbor stage | | | | |
| I-II | 26 (9%) | 26 (12%) | 0 (0%) | <0.001 |
| III-IV | 264 (91%) | 182 (88%) | 82 (100%) | |
| ECOS PS | | | | |
| 0-1 | 238 (82%) | 175 (84%) | 63 (77%) | 0.11 |
| ≥2 | 47 (16%) | 29 (14%) | 18 (22%) | |
| missing | 5 (2%) | 4 (2%) | 1 (1%) | |
| Extranodal sites | | | | |
| <2 | 143 (49%) | 117 (56%) | 26 (32%) | <0.000 1 |
| ≥2 | 147 (51%) | 91 (44%) | 56 (68%) | |
| Elevated LDH > ULN | | | | |
| No | 111 (38%) | 84 (40%) | 27 (33%) | 0.28 |
| Yes | 175 (60%) | 121 (58%) | 54 (66%) | |
| missing | 4 (2%) | 3 (2%) | 1 (1%) | |
| MTV | | | | |
| <220 cm ³ | 132 (45%) | 109 (52%) | 23 (28%) | <0.001 |
| >220 cm ³ | 158 (55%) | 99 (48%) | 59 (72%) | |
| IPI | | | | |
| <3 | 81 (28%) | 71 (34%) | 10 (12%) | <0.001 |
| ≥3 | 205 (71%) | 135 (65%) | 70 (85%) | |
| missing | 4 (1%) | 2 (1%) | 2 (2%) | |
| NCCN-IPI | | | | |
| Low intermediate | 72 (25%) | 62 (30%) | 11 (13%) | 0.006 |
| high intermediate and high | 201 (70%) | 133 (64%) | 67 (82%) | |
| Missing | 17 (5%) | 13 (6%) | 4 (5%) | |
| Treatment arm for maintenance | | | | |
| Placebo arm | 140 (48%) | 106 (51%) | 34 (42%) | 0.15 |
| Lenalidomide arm | 150 (52%) | 102 (49%) | 48 (58%) | |

| | | | | |
|-------------------------------------|-----------|-----------|----------|-------|
| CNS relapse | | | | |
| No | 283 (98%) | 205 (99%) | 78 (95%) | 0.10 |
| Yes | 7 (2%) | 3 (1%) | 4 (5%) | |
| BCL2 expression (%) | | | | |
| <50% | 19 (15%) | 16 (19%) | 3 (8%) | 0.18 |
| ≥50% | 104 (85%) | 69 (81%) | 35 (92%) | |
| missing | 167 | 123 | 44 | |
| MYC expression (%) | | | | |
| < 40% | 56 (58%) | 41 (61%) | 15 (50%) | 0.38 |
| ≥ 40% | 41 (42%) | 26 (39%) | 15 (50%) | |
| missing | 193 | 141 | 52 | |
| Double expressor | | | | |
| No | 67 (65%) | 50 (69%) | 17 (55%) | 0.18 |
| yes | 36 (35%) | 22 (31%) | 14 (45%) | |
| missing | 187 | 136 | 51 | |
| GCB/ABC profile (nanostring) | | | | |
| ABC | 71 (36%) | 44 (32%) | 27 (46%) | 0.073 |
| GCB | 96 (49%) | 71 (51%) | 25 (43%) | |
| Unclassified | 23 (12%) | 20 (14%) | 3 (5%) | |
| NA/missing | 7/93 | 4/69 | 3/24 | |
| GCB/non GCB profile (hans) | | | | |
| GCB | 88 (48%) | 63 (48%) | 25 (47%) | 0.99 |
| Non-GCB | 97 (52%) | 69 (52%) | 28 (53%) | |
| missing | 105 | 76 | 29 | |

LDH=lactate dehydrogenase IPI=International Prognostic Index, aaIPI=age adjusted IPI, NCCN-IPI = National Comprehensive Cancer Network IPI.

Table 2: Univariate Analyses for Progression-Free Survival (PFS) and Overall Survival (OS)

| Characteristics | Univariate analysis of PFS | | Univariate analysis of OS | |
|------------------------------|----------------------------|----------|---------------------------|----------|
| | HR (95% CI) | <i>P</i> | HR (95% CI) | <i>P</i> |
| Female | 0.9 (0.6-1.3) | 0.49 | 0.8 (0.5-1.4) | 0.40 |
| Ann Arbor stage III-IV | 1.9 (0.8-4.6) | 0.16 | 2.8 (0.7-11.5) | 0.15 |
| Elevated LDH (> ULN) | 1.2 (0.8-1.9) | 0.38 | 1.3 (0.7-2.3) | 0.36 |
| Extranodal sites > 1 | 1.9 (1.2-2.9) | 0.0031 | 2.2 (1.2-3.8) | 0.0068 |
| ECOG 2-3 | 2.5 (1.5-4.0) | 0.0002 | 2.7 (1.5-4.8) | 0.0007 |
| IPI 3-5 | 1.8 (1.1-3.0) | 0.03 | 2.8 (1.3-6.3) | 0.0099 |
| NCCN-IPI High | 1.5 (1.0-2.0) | 0.024 | 1.9 (1.2-2.9) | 0.0049 |
| MTV >220 cm ³ | 2.5 (1.6-3.9) | 0.0001 | 3.7 (1.9-7.2) | 0.0001 |
| Dmax > 0.47 m | 2.3 (1.5-3.5) | 0.0001 | 2.3 (1.3-3.8) | 0.0024 |
| SDmax > 0.32 m ⁻¹ | 2.7 (1.8-4.2) | <0.0001 | 2.3 (1.3-3.9) | 0.0027 |

Table 3 : Multivariate Analyses for Progression-Free Survival (PFS) and Overall Survival (OS)

| Characteristics | Multivariate analysis of PFS | | Multivariate analysis of OS | |
|-------------------------------------|------------------------------|--------|-----------------------------|--------|
| | HR (95% CI) | P | HR (95% CI) | P |
| <i>Model 1</i> | | | | |
| High SDmax > 0.32 m ⁻¹ | 2.4 (1.6-3.7) | 0.0001 | 1.8 (1.1-3.2) | 0.028 |
| MTV>220cm ³ | 2.2 (1.4-3.5) | 0.0010 | 3.3 (1.7-6.5) | 0.0004 |
| <i>Model 2 : individual factors</i> | | | | |
| High SDmax > 0.32 m ⁻¹ | 2.3 (1.5-3.6) | 0.0001 | - | - |
| MTV>220cm ³ | 2.0 (1.2-3.2) | 0.037 | 2.9 (1.5-5.8) | 0.0021 |
| ECOG 2-3 | 2.3 (1.4-3.7) | 0.0010 | 2.2 (1.3-4.0) | 0.0063 |
| Extranodal sites > 1 | - | - | - | - |
| <i>Model 3</i> | | | | |
| High SDmax > 0.32 m ⁻¹ | 2.4 (1.6-3.7) | 0.0001 | 1.7 (1.0-3.0) | 0.061 |
| MTV>220cm ³ | 2.1 (1.3-3.4) | 0.0016 | 3.3 (1.7-6.4) | 0.0006 |
| IPI 3-5 | - | - | - | - |

Figures legends

Figure 1: Scatter diagram showing the correlation between SDmax and the number of nodal areas involved.

Figure 2 Kaplan–Meier estimates of progression-free survival (PFS) and overall survival (OS) according to SDmax (A,B) and according to SDmax and baseline metabolic tumour volume (C,D).

Figure 3: Maximal intensity projection of patients with low risk (low MTV and low SDmax), intermediate risk (high MTV with low SDmax or low MTV with high SDmax), and high risk (high MTV and high SDmax)